Skip to main

OncoCyte

OCX is nowIMDX
OCX logo
This stock has changed its ticker name. This happens for a variety of reason, including a corporate merger or simply a change in company name.
Learn More
Go to the new stock page

Frequently Asked Questions (FAQ)

As of Jul 26, 2025, the market cap for OncoCyte stock is $82.51M

The current P/E ratio for OncoCyte stock is -0.82

The 52-week high for OncoCyte stock is $4.75. The current OncoCyte stock price $undefined is 100.00% below its 52-week high

The 52-week low for OncoCyte stock is $1.92. The current OncoCyte stock price $undefined has increased 100.00% from its 52-week low

No, the OncoCyte stock does not pay dividends to its shareholders

The target price for OncoCyte stock is $4.53 based on the average of what a group of analyst think OncoCyte stock could be worth at a future date. This is not a prediction by Public.com

How to buy OncoCyte stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in OncoCyte stock

    Navigate to the Explore page. Then, type OncoCyte into the search bar. When you see OncoCyte stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased OncoCyte stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Buy OncoCyte (OCX) Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.